Theriva Biologics, Inc. 8-K

What Happened
On March 23, 2026 Theriva Biologics (TOVX) issued a press release and filed an 8‑K reporting the outcomes of a Type B End‑of‑Phase 2 (EOP2) meeting with the U.S. FDA. The agency provided general agreement with the company’s proposed Phase 3 study design for VCN-01 in combination with gemcitabine/nab‑paclitaxel for metastatic pancreatic adenocarcinoma (PDAC). The FDA indicated that a successful Phase 3 could support a biologics license application (BLA) and agreed on key design elements including repeat dosing, an adaptive design, and overall survival (OS) as the primary endpoint.

Key Details

• Date: press release and 8‑K filed March 23, 2026.
• Phase 3 design: randomized, double‑blind trial comparing VCN‑01 + gemcitabine/nab‑paclitaxel vs. gemcitabine/nab‑paclitaxel + placebo.
• Endpoints and design: OS as primary endpoint; key secondary endpoints include progression‑free survival (PFS); adaptive design with planned interim analyses and potential sample‑size re‑estimation.
• Dosing and rationale: FDA agreed to the proposed repeat “macrocycle” dosing (allowing more than two doses), reflecting VIRAGE Phase 2 results announced in 2025 where two doses produced greater OS and PFS improvements versus standard of care.

Why It Matters
For investors, FDA agreement on core trial design, endpoints and dosing reduces regulatory uncertainty for the planned Phase 3 and clarifies a potential pathway to a BLA if the trial is successful. The filing ties directly to the positive VIRAGE Phase 2 readout (2025), which showed improved OS, PFS and duration of response with VCN‑01; the Phase 3 will test whether those benefits hold in a larger, randomized setting. This is a material clinical development event, but it does not guarantee trial success or approval—results from the Phase 3 will determine the next regulatory steps.